You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Improving treatment options and outcomes in fungal keratitis

    SBC: TranZ Biosciences LLC            Topic: N

    ABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: Virogenomics BioDevelopment Inc            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Process for GMP Production of Natural THC and CBD

    SBC: ElSohly Laboratories, Incorporated            Topic: R41

    Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with potential therapeutic value in several disease conditionsWhileTHC has already been in use clinically for two indicationsnausea and vomiting in cancer patients receiving chemotherapy and appetite stimula ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a lead cyclic-PDZ-Enhancer drug for Anxiety and Depression

    SBC: Aingeal, LLC            Topic: 101

    Major depressive disorder is a debilitating mood disorder that affects ~7% of US adults in their lifetime, costing the U.S. economy more than $200 billion a year. Drugs that increase monoaminergic signaling are the mainstay of depression therapy, but have a delayed onset of action and are only effective in about 50% of affected patients. Aberrant brain-derived neurotrophic factor (BDNF) signaling ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes

    SBC: CellGro Technologies, LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Therapy for Myasthenia Gravis

    SBC: ARC Biotechnology LLC            Topic: NINDS

    Myasthenia gravis is a severe neuromuscular disease primarily caused by complement activating autoantibodies directed towards the skeletal muscle acetylcholine receptor. Present treatments are ineffectiveand uniformly have adverse effects, which negatively impact quality of life. Despite being a rare disease, myasthenia gravis is a costly one with a hospitalization expense of half a billion dollar ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Novel High-Resolution Scintillation X-ray Detectors for Digital Dentistry

    SBC: NGS Detectors LLC            Topic: NIDCR

    Project SummaryNovel High Resolution Scintillation X ray Detectors for Digital Dentistry The transition from traditional film to digital X ray detectors has resulted in significant improvements across many areas for dental X ray imaging ranging from decreased wait timesimproved logistics and even lower radiation dose ratesOne significant drawback remains with digital X ray imaging howeverwhich is ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. C.A.R.E.S.: A Mobile Health Program for Alcohol Risk Reduction for an Under-Served College Population

    SBC: Live Inspired, LLC            Topic: 550

    Excessive alcohol use is the third-leading preventable cause of death in the U.S. with young adults ages 18-29 showing the highest rates of hazardous alcohol use. Community colleges serve over 12 million students, comprising 45% of all U.S. college students. Community college students (CCS) show rates of heavy alcohol use similar to students at traditional four-year residential (FYR) colleges, but ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: Virogenomics BioDevelopment Inc            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government